XΔ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling

Cell

Volumn 155, Issue 5, 2013, Pages 1154-

  Chen, Rongqing ^a   Zhang, Jian ^a   Fan, Ni ^a   Teng, Zhao Qian ^a   Wu, Yan ^a   Yang, Hongwei ^a   Tang, Ya Ping ^b   Sun, Hao ^a   Song, Yunping ^a   Chen, Chu ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CELECOXIB; CYCLOOXYGENASE 2; DRONABINOL; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROSTANOID; PROTEIN KINASE B;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN NERVE CELL; CATALEPSY; CELL DENSITY; CONTROLLED STUDY; DENDRITIC SPINE; DOSE RESPONSE; DOWN REGULATION; DRUG RECEPTOR BINDING; DRUG REEXPOSURE; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEAR; HIPPOCAMPUS; INTERNALIZATION; INTRACELLULAR SIGNALING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; WORKING MEMORY;

ANIMALIA; CANNABIS SATIVA;

EID: 84889598272     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2013.10.042     Document Type: Article

References (61)

1. Alger, B.E. (2009). Endocannabinoid signaling in neural plasticity. Curr. Top. Behav. Neurosci. 1, 141-172.
2. Akaneya, Y., and Tsumoto, T. (2006). Bidirectional trafficking of prostaglandin E2 receptors involved in long-term potentiation in visual cortex. J. Neurosci. 26, 10209-10221.
3. Bahr, B.A., Karanian, D.A., Makanji, S.S., and Makriyannis, A. (2006). Targeting the endocannabinoid system in treating brain disorders. Expert Opin. Investig. Drugs 15, 351-365.
4. Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., Rizzini, B.L., Pozzan, T., and Volterra, A. (1998). Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391, 281-285.
5. Brock, T.G., McNish, R.W., and Peters-Golden, M. (1999). Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J. Biol. Chem. 274, 11660-11666.
6. Burstein, S.H., Hull, K., Hunter, S.A., and Shilstone, J. (1989). Immunization against prostaglandins reduces delta 1-tetrahydrocannabinol-induced catalepsy in mice. Mol. Pharmacol. 35, 6-9.
7. Campbell, V.A., and Gowran, A. (2007). Alzheimer's disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 152, 655-662.
8. Carlini, E.A. (2004). The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (D 9-THC) on humans. Toxicon 44, 461-467.
9. Centonze, D., Finazzi-Agrò, A., Bernardi, G., and Maccarrone, M. (2007). The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 28, 180-187.
10. Chen, C., Magee, J.C., and Bazan, N.G. (2002). Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J. Neurophysiol. 87, 2851-2857.
11. Chen, X., Zhang, J., and Chen, C. (2011). Endocannabinoid 2-arachidonoylglycerol protects neurons against b-amyloid insults. Neuroscience 178, 159-168.
12. Chen, C., Hardy, M., Zhang, J., LaHoste, G.J., and Bazan, N.G. (2006a). Altered NMDA receptor trafficking contributes to sleep deprivation-induced hippocampal synaptic and cognitive impairments. Biochem. Biophys. Res. Commun. 340, 435-440.
13. Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.P., Teng, Z., and Chen, C. (2012). Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2, 1329-1339.
14. Chevaleyre, V., Takahashi, K.A., and Castillo, P.E. (2006). Endocannabinoidmediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29, 37-76.
15. Cowley, T.R., Fahey, B., and O'Mara, S.M. (2008). COX-2, but not COX-1, activity is necessary for the induction of perforant path long-term potentiation and spatial learning in vivo. Eur. J. Neurosci. 27, 2999-3008.
16. Dave, K.A., Platel, J.C., Huang, F., Tian, D., Stamboulian-Platel, S., and Bordey, A. (2010). Prostaglandin E2 induces glutamate release from subventricular zone astrocytes. Neuron Glia Biol. 6, 201-207.
17. Delaney, A.J., Crane, J.W., and Sah, P. (2007). Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron 56, 880-892.
18. Du, H., Chen, X., Zhang, J., and Chen, C. (2011). Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-g. Br. J. Pharmacol. 163, 1533-1549.
19. Egashira, N., Koushi, E., Mishima, K., Iwasaki, K., Oishi, R., and Fujiwara, M. (2007). 2,5-Dimethoxy-4-iodoamphetamine (DOI) inhibits Delta9-tetrahydrocannabinol- induced catalepsy-like immobilization in mice. J. Pharmacol. Sci. 105, 361-366.
20. Fairbairn, J.W., and Pickens, J.T. (1979). The oral activity of delta'-tetrahydrocannabinol and its dependence on prostaglandin E2. Br. J. Pharmacol. 67, 379-385.
21. Fairbairn, J.W., and Pickens, J.T. (1980). The effect of conditions influencing endogenous prostaglandins on the activity of delta'- tetrahydrocannabinol in mice. Br. J. Pharmacol. 69, 491-493.
22. Fan, N., Yang, H., Zhang, J., and Chen, C. (2010). Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo D9-THC exposure-impaired hippocampal synaptic plasticity. J. Neurochem. 112, 691-702.
23. Ferraro, L., Tomasini, M.C., Gessa, G.L., Bebe, B.W., Tanganelli, S., and Antonelli, T. (2001). The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb. Cortex 11, 728-733.
24. Gaoni, Y., and Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647.
25. Goubaeva, F., Ghosh, M., Malik, S., Yang, J., Hinkle, P.M., Griendling, K.K., Neubig, R.R., and Smrcka, A.V. (2003). Stimulation of cellular signaling and G protein subunit dissociation by G protein betagamma subunit-binding peptides. J. Biol. Chem. 278, 19634-19641.
26. Gowran, A., Noonan, J., and Campbell, V.A. (2011). The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci. Ther. 17, 637-644.
27. Guo, J., and Ikeda, S.R. (2004). Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol. Pharmacol. 65, 665-674.
28. Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F., Koehl, M., Abrous, D.N., Mendizabal-Zubiaga, J., Grandes, P., et al. (2012). Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148, 1039-1050.
29. Hoffman, A.F., Oz, M., Yang, R., Lichtman, A.H., and Lupica, C.R. (2007). Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn. Mem. 14, 63-74.
30. Howlett, A.C. (1998). The CB1 cannabinoid receptor in the brain. Neurobiol. Dis. 5(6 Pt B), 405-416.
31. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., and Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89, 309-380.
32. Li, S., Jin, M., Koeglsperger, T., Shepardson, N.E., Shankar, G.M., and Selkoe, D.J. (2011). Soluble Ab oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 6627-6638.
33. Lichtman, A.H., and Martin, B.R. (1996). Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl.) 126, 125-131.
34. Long, J.Z., Nomura, D.K., Vann, R.E., Walentiny, D.M., Booker, L., Jin, X., Burston, J.J., Sim-Selley, L.J., Lichtman, A.H., Wiley, J.L., and Cravatt, B.F. (2009). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. USA 106, 20270-20275.
35. Lovinger, D.M. (2008). Presynaptic modulation by endocannabinoids. Handbook Exp. Pharmacol. 184, 435-477.
36. Marchalant, Y., Brothers, H.M., and Wenk, G.L. (2008). Inflammation and aging: can endocannabinoids help? Biomed. Pharmacother. 62, 212-217.
37. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S.C., Cascio, M.G., Gutiérrez, S.O., van der Stelt, M., et al. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88.
38. Mato, S., Chevaleyre, V., Robbe, D., Pazos, A., Castillo, P.E., and Manzoni, O.J. (2004). A single in-vivo exposure to delta 9THC blocks endocannabinoid- mediated synaptic plasticity. Nat. Neurosci. 7, 585-586.
39. Mato, S., Robbe, D., Puente, N., Grandes, P., and Manzoni, O.J. (2005). Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J. Neurosci. 25, 11619-11627.
40. Messinis, L., Kyprianidou, A., Malefaki, S., and Papathanasopoulos, P. (2006). Neuropsychological deficits in long-term frequent cannabis users. Neurology 66, 737-739.
41. Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C.T., Lutz, B., and Marsicano, G. (2007). Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 5, e269.
42. Navarrete, M., and Araque, A. (2008). Endocannabinoids mediate neuronastrocyte communication. Neuron 57, 883-893.
43. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., and Shohami, E. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
44. Perez-Reyes, M., Burstein, S.H., White, W.R., McDonald, S.A., and Hicks, R.E. (1991). Antagonism of marihuana effects by indomethacin in humans. Life Sci. 48, 507-515.
45. Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P., Di Marzo, V., Elphick, M.R., Greasley, P.J., Hansen, H.S., Kunos, G., Mackie, K., et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631.
46. Pope, H.G., Jr., Gruber, A.J., Hudson, J.I., Huestis, M.A., and Yurgelun-Todd, D. (2001). Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry 58, 909-915.
47. Puighermanal, E., Marsicano, G., Busquets-Garcia, A., Lutz, B., Maldonado, R., and Ozaita, A. (2009). Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat. Neurosci. 12, 1152-1158.
48. Robson, P. (2001). Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry 178, 107-115.
49. Rubino, T., Realini, N., Braida, D., Guidi, S., Capurro, V., Viganò, D., Guidali, C., Pinter, M., Sala, M., Bartesaghi, R., and Parolaro, D. (2009). Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19, 763-772.
50. Russo, E.B. (2007). History of cannabis and its preparations in saga, science, and sobriquet. Chem. Biodivers. 4, 1614-1648.
51. Sang, N., Zhang, J., Marcheselli, V., Bazan, N.G., and Chen, C. (2005). Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J. Neurosci. 25, 9858-9870.
52. Sanzgiri, R.P., Araque, A., and Haydon, P.G. (1999). Prostaglandin E(2) stimulates glutamate receptor-dependent astrocyte neuromodulation in cultured hippocampal cells. J. Neurobiol. 41, 221-229.
53. Solowij, N., Stephens, R.S., Roffman, R.A., Babor, T., Kadden, R., Miller, M., Christiansen, K., McRee, B., and Vendetti, J.; Marijuana Treatment Project Research Group. (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287, 1123-1131.
54. Suárez, I., Bodega, G., Fernández-Ruiz, J., Ramos, J.A., Rubio, M., and Fernández, B. (2004). Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal D9-tetrahydrocannabinol exposure. Cerebellum 3, 66-74.
55. Suárez, I., Bodega, G., Rubio, M., Fernández-Ruiz, J.J., Ramos, J.A., and Fernández, B. (2004). Prenatal cannabinoid exposure down- regulates glutamate transporter expressions (GLAST and EAAC1) in the rat cerebellum. Dev. Neurosci. 26, 45-53.
56. Teather, L.A., Packard, M.G., and Bazan, N.G. (2002). Post-training cyclooxygenase- 2 (COX-2) inhibition impairs memory consolidation. Learn. Mem. 9, 41-47.
57. Tomasini, M.C., Ferraro, L., Bebe, B.W., Tanganelli, S., Cassano, T., Cuomo, V., and Antonelli, T. (2002). D(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors. J. Neurosci. Res. 68, 449-453.
58. Tonini, R., Ciardo, S., Cerovic, M., Rubino, T., Parolaro, D., Mazzanti, M., and Zippel, R. (2006). ERK-dependent modulation of cerebellar synaptic plasticity after chronic D9-tetrahydrocannabinol exposure. J. Neurosci. 26, 5810-5818.
59. Wilson, R.I., Kunos, G., and Nicoll, R.A. (2001). Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31, 453-462.
60. Yao, L., Fan, P., Jian, Z., Mailliard, W.S., Gordon, A.S., and Diamond, I. (2003). Addicitng drugs untilize a synergistic molecular mechanism in common requiring adenosine and Gi-bg dimmers. Proc. Natl. Acad. Sci. USA 100, 14379-14384.
61. Zhang, J., and Chen, C. (2008). Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283, 22601- 22611.